NCT03016195

Brief Summary

Oral sodium supplementation is currently administered in cases of poor weight gain in infants particularly in patients who have undergone gastrointestinal surgical procedures. The decision to start oral supplementation is based on urinary sodium levels although the level at which to start treatment is variable as the range in normal, healthy infants is unknown. This study aims to ascertain the normal range of sodium in urine specimens collected from healthy newborn babies. It is believed that by increasing the level of salt in the intestine, glucose can be more easily be absorbed and therefore weight gain improved. Babies with conditions where they are at risk of salt depletion (i.e. those with a stoma) are currently administered oral sodium supplementation if they are failing to gain weight and have an associated 'low' urinary sodium level. Low levels of urinary sodium are considered to represent a state of low body sodium levels, as the kidneys attempt to reabsorb most of the sodium in the urine before it is excreted. Current practice varies widely as to the level below which treatment should be instigated. Some centres advise below 20 mmol/L (Birmingham Children's Hospital and Nottingham Children's Hospital guidelines), others below 10 mmol/L (University Children's Hospital, Zurich). In Glasgow, babies with poor weight gain are given sodium supplementation if urinary sodium levels are below 40 mmol/L. There are no documented ranges for the levels of urinary sodium in healthy, newborn babies. By determining the reference range of urinary sodium levels in healthy, term babies who are gaining weight appropriately, the investigators hope to be able to have a better understanding about both the level below which supplementation should be considered and the target range that should be aimed for.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Oct 2016

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2016

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

January 6, 2017

Completed
4 days until next milestone

First Posted

Study publicly available on registry

January 10, 2017

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2017

Completed
Last Updated

May 8, 2017

Status Verified

May 1, 2017

Enrollment Period

6 months

First QC Date

January 6, 2017

Last Update Submit

May 3, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • Random urinary sodium concentration (mmol/L)

    Approximately 6 weeks after birth - sample asked to be collected by parents at 6 weeks of age

Secondary Outcomes (2)

  • Weight velocity (by World Health Organization growth chart centiles)

    Birth weight to weight at 6 weeks

  • Feeding practices - which milk type mothers use to feed their babies e.g. exclusive breastmilk, exclusive formula, mixed

    At birth and 6 weeks

Eligibility Criteria

AgeUp to 7 Days
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

The population being studied is healthy term (37-41 week gestation) babies with no significant ante- or post-natal history born within the study period in a single maternity unit.

You may qualify if:

  • Term (37-41 week gestation) infant
  • Born at specified maternity unit within study period
  • Uncomplicated pregnancy with no antenatal diagnosis
  • Uncomplicated postnatal period: no admission to neonatal/special care unit
  • Full enteral milk feeds since birth

You may not qualify if:

  • \< 37/40 gestation or \> 41/40 gestation infants
  • Antenatal diagnosis of congenital abnormality
  • Postnatal admission to the neonatal unit/special care baby unit
  • Period of total parenteral nutrition

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Royal Hospital for Children Glasgow

Glasgow, South Lanarkshire, G51 4TF, United Kingdom

Location

Related Publications (1)

  • Cullis PS, Cull F, Bruce G, Johnston A, Patel H, Jackson L, Galloway P, Walker G. Quantification of urinary sodium concentrations in term infants. Ann Clin Biochem. 2019 Mar;56(2):295-297. doi: 10.1177/0004563218796592. Epub 2018 Aug 21.

MeSH Terms

Conditions

Failure to Thrive

Condition Hierarchy (Ancestors)

Signs and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Honorary clinical lecturer

Study Record Dates

First Submitted

January 6, 2017

First Posted

January 10, 2017

Study Start

October 1, 2016

Primary Completion

April 1, 2017

Study Completion

April 1, 2017

Last Updated

May 8, 2017

Record last verified: 2017-05

Data Sharing

IPD Sharing
Will not share

Locations